U.S. markets closed

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
208.32-27.29 (-11.58%)
At close: 04:00PM EST
209.00 +0.68 (+0.33%)
After hours: 07:55PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close235.61
Bid209.14 x 1300
Ask226.00 x 800
Day's Range194.88 - 227.94
52 Week Range57.21 - 322.67
Avg. Volume489,321
Market Cap4.113B
Beta (5Y Monthly)-0.43
PE Ratio (TTM)N/A
EPS (TTM)-19.25
Earnings DateFeb 21, 2024 - Feb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est315.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MDGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Madrigal Pharmaceuticals, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Motley Fool

    These 2 Stocks Could Be About to Soar: Are They Buys?

    Shares of relatively small biotech companies often soar when they get positive news from regulators, and that's exactly what Madrigal Pharmaceuticals (NASDAQ: MDGL) and Bluebird Bio (NASDAQ: BLUE) are awaiting. Madrigal Pharmaceuticals is a clinical-stage biotech that may have made a significant breakthrough. Madrigal submitted an application for resmetirom, its potential NASH therapy, to the Food and Drug Administration (FDA) for review in July.

  • GlobeNewswire

    Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    CONSHOHOCKEN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Carole Huntsman, the Company’s new Chief Commercial Officer and Senior Vice President and (ii) twelve other new employees, in each case with a grant date of November 20, 2023, as equity inducement awards under the terms of the

  • Insider Monkey

    11 Best Upside Stocks To Buy Right Now

    In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […]